Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ERA 25: Switching from sMRAs to Finerenone
Author(s): Beatriz Fernandez Fernandez Added: 6 months ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of… View more

Cardiovascular Renal Metabolic
Renal Impact: Rivaroxaban Versus Vitamin K Antagonists in AF
Author(s): Phong Phan Dinh , Tri Huynh Quang Ho , Hung Manh Pham , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
The Coronary Microcirculation Re-explored
Author(s): Ahmed Elamin , Mustafa Abdimalik , Mohanad Abdelrahim , et al Added: 1 month ago

Prevention & Chronic Conditions
ESC 23: MULTISTARS AMI Trial
Author(s): Linda Joosten Added: 2 years ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial. FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists … View more

Anticoagulation

Demographic
Selecting NOAC to Optimise Stroke Prevention in AF – Part 1
Author(s): Tri Huynh Quang Ho , Minh That Ton , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 6 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Renal Metabolic

Heart Failure
Selecting NOAC to Optimise Stroke Prevention in AF – Part 2
Author(s): Minh That Ton , Tri Huynh Quang Ho , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
EHRA 24: A Substudy of NOAH-AFNET 6
Author(s): Julius Nikorowitsch Added: 1 year ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from… View more

Electrophysiology & Arrhythmia
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 1 month ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Recent Advances in Pulmonary Hypertension
Author(s): Akshyaya Pradhan , Richa Tyagi , Prachi Sharma , et al Added: 11 months ago

Heart Failure

Prevention & Chronic Conditions